UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

Clinical pharmacokinetics, 2019-01, Vol.58 (1), p.15-37

2019

Volltextzugriff (PDF)

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

Alimentary pharmacology & therapeutics, 2019-02, Vol.49 (3), p.265-276

2019

Volltextzugriff (PDF)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease

Alimentary pharmacology & therapeutics, 2021-03, Vol.53 (5), p.587-597

2021

Volltextzugriff (PDF)

Infliximab biosimilar CT-P13 in Crohn's disease

The Lancet (British edition), 2019-04, Vol.393 (10182), p.1671-1672

2019

Volltextzugriff (PDF)

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease

PloS one, 2018-01, Vol.13 (1), p.e0190999-e0190999

2018

Volltextzugriff (PDF)

S1429 Efficacy of Guselkumab in Moderately to Severely Active Crohn’s Disease According to Induction Clinical Response Status: Week 48 Results from the GALAXI 2 & 3 Phase 3 Trials

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S1024-S1025

2024

Volltextzugriff (PDF)

S1330 Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S953-S953

2024

Volltextzugriff (PDF)

S1453 Disease Characteristics Associated With Bowel Urgency in Crohn’s Disease: Results From the Phase 3 VIVID-1 Trial

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S1046-S1046

2024

Volltextzugriff (PDF)

S1445 Efficacy of Guselkumab vs Placebo in Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S1039-S1040

2024

Volltextzugriff (PDF)

S1052 Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S740-S741

2024

Volltextzugriff (PDF)

S1452 Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 VIVID-1 Study

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S1045-S1045

2024

Volltextzugriff (PDF)

S1329 Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn’s Disease

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S952-S953

2024

Volltextzugriff (PDF)

S1050 Efficacy and Safety of Upadacitinib Maintenance Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Two Year Results From the U-ENDURE Long-Term Extension Study

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S737-S739

2024

Volltextzugriff (PDF)

S1079 Mirikizumab Effect on Bowel Urgency Resolution in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S763-S763

2024

Volltextzugriff (PDF)

S1446 Efficacy and Safety of Long-Term Mirikizumab Treatment in Patients With Moderate to Severe Crohn’s Disease

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S1040-S1041

2024

Volltextzugriff (PDF)

An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials

Alimentary Pharmacology & Therapeutics (Suppl), 2021-04, Vol.53 (7), p.784-793

2021

Volltextzugriff (PDF)

S1083 Etrasimod for Moderately to Severely Active Crohn’s Disease: Results From the Extension Period of a Phase 2 Study

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S767-S768

2024

Volltextzugriff (PDF)

S1127 A Randomized, Double-Blind, Placebo-Controlled Trial of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease: Design and Rationale for the VICTRIVA Study

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S800-S800

2024

Volltextzugriff (PDF)

Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease

Clinical imaging, 2020-02, Vol.59 (2), p.179-187

2020

Volltextzugriff (PDF)

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Therapeutic drug monitoring, 2018-04, Vol.40 (2), p.202-211

2018

Volltextzugriff (PDF)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up

United European gastroenterology journal, 2022-03, Vol.10 (2), p.160-168

2022

Volltextzugriff (PDF)

Biosimilars in IBD: hope or expectation?

Gut, 2013-06, Vol.62 (6), p.803-807

2013

Volltextzugriff (PDF)

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease

Cells (Basel, Switzerland), 2022-09, Vol.11 (18), p.2846

2022

Volltextzugriff (PDF)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

United European gastroenterology journal, 2023-06, Vol.11 (5), p.410-422

2023

Volltextzugriff (PDF)

Whole-Genome DNA Methylation Profiling of CD14+ Monocytes Reveals Disease Status and Activity Differences in Crohn's Disease Patients

Journal of clinical medicine, 2020-04, Vol.9 (4), p.1055

2020

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

ThemaCrohns Disease

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Remission
(23)
Patients
(21)
Humans
(20)
Crohn's Disease
(17)
Endoscopy
(16)
Adult
(13)
Female
(13)
Gastroenterology & Hepatology
(12)
Inflammatory Bowel Disease
(12)
Male
(11)
Clinical Trials
(9)
Treatment Outcome
(9)
Crohn Disease - Drug Therapy
(8)
Pharmacology & Pharmacy
(8)
Infliximab
(7)
Middle Aged
(7)
Antibodies, Monoclonal - Therapeutic Use
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease

Infliximab biosimilar CT-P13 in Crohn's disease

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease

S1429 Efficacy of Guselkumab in Moderately to Severely Active Crohn’s Disease According to Induction Clinical Response Status: Week 48 Results from the GALAXI 2 & 3 Phase 3 Trials

S1330 Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease

S1453 Disease Characteristics Associated With Bowel Urgency in Crohn’s Disease: Results From the Phase 3 VIVID-1 Trial

S1445 Efficacy of Guselkumab vs Placebo in Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies

S1052 Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study

S1452 Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 VIVID-1 Study

S1329 Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn’s Disease

S1050 Efficacy and Safety of Upadacitinib Maintenance Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Two Year Results From the U-ENDURE Long-Term Extension Study

S1079 Mirikizumab Effect on Bowel Urgency Resolution in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease

S1446 Efficacy and Safety of Long-Term Mirikizumab Treatment in Patients With Moderate to Severe Crohn’s Disease

An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials

S1083 Etrasimod for Moderately to Severely Active Crohn’s Disease: Results From the Extension Period of a Phase 2 Study

S1127 A Randomized, Double-Blind, Placebo-Controlled Trial of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease: Design and Rationale for the VICTRIVA Study

Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up

Biosimilars in IBD: hope or expectation?

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

Whole-Genome DNA Methylation Profiling of CD14+ Monocytes Reveals Disease Status and Activity Differences in Crohn's Disease Patients

Aktive Filter

Suchergebnisse filtern